Pulmonary Hypertension
Our focus in pulmonary hypertension
At Johnson & Johnson Innovative Medicine (J&J) UK, our focus is on Pulmonary Arterial Hypertension (PAH) — a specific, rare form of pulmonary hypertension (PH).1
We are spearheading a new era for those living with PAH to transform the disease into a long-term manageable condition, so that patients can live fulfilling lives.
We are spearheading a new era for those living with PAH to transform the disease into a long-term manageable condition, so that patients can live fulfilling lives.
What is PAH?
There are five groups of PH, a condition that leads to high blood pressure in the blood vessels.1
In the UK, approximately 55 people per million—nearly 4,000 individuals—are affected by PAH.1,2
The risk of developing PAH increases with age and is particularly relevant for those living with conditions such as Scleroderma, Congenital Heart Disease, or other Connective Tissue Disorders (CTD).1 Our focus is therefore on supporting people in these groups with diagnosis and managing the condition.
With PAH, symptoms might not appear until the condition is advanced, meaning the condition can be difficult to diagnose.1
In the UK, approximately 55 people per million—nearly 4,000 individuals—are affected by PAH.1,2
The risk of developing PAH increases with age and is particularly relevant for those living with conditions such as Scleroderma, Congenital Heart Disease, or other Connective Tissue Disorders (CTD).1 Our focus is therefore on supporting people in these groups with diagnosis and managing the condition.
With PAH, symptoms might not appear until the condition is advanced, meaning the condition can be difficult to diagnose.1
We understand how PAH impairs daily life
PAH remains a severely debilitating condition that can lead to heart disease and early death. It also continues to be very difficult to diagnose.3 Yet, early diagnosis and treatment are crucial to helping improve life expectancy. Reducing this time to a diagnosis is therefore one of our core missions.1
We have demonstrated our UK commitment to PAH over the past five years through:
We have demonstrated our UK commitment to PAH over the past five years through:
100
Medical education meetings
20
UK grants and donations
8
Clinical publications
275
Patients enrolled in clinical trials
Our Vision in PAH
We are committed to transforming the lives of people affected by PAH through innovation and collaboration.
At J&J, our vision in PAH is centered on reducing diagnosis time by supporting education and screening to accelerate referrals to specialists. We are committed to improving the health and quality of life of those affected by PAH, including patients, carers, and families. Through partnerships with the NHS, we aim to empower healthcare professionals and enhance PAH management across the UK healthcare system, while maximising the clinical benefits of our treatments for better patient outcomes. We are driving research and innovation to discover new ways to tackle PAH, and together with patients, healthcare professionals, and advocates, we are making meaningful progress to improve lives and advance PAH care.
At J&J, our vision in PAH is centered on reducing diagnosis time by supporting education and screening to accelerate referrals to specialists. We are committed to improving the health and quality of life of those affected by PAH, including patients, carers, and families. Through partnerships with the NHS, we aim to empower healthcare professionals and enhance PAH management across the UK healthcare system, while maximising the clinical benefits of our treatments for better patient outcomes. We are driving research and innovation to discover new ways to tackle PAH, and together with patients, healthcare professionals, and advocates, we are making meaningful progress to improve lives and advance PAH care.
As part of our ongoing commitment to advancing PAH care, we are proud to share our PAH podcast series. Through expert insights and real-world experiences, these podcasts aim to educate and engage the healthcare community, further supporting the drive to improve diagnosis, treatment, and outcomes for those affected by PAH.
You are now leaving Johnson & Johnson Innovative Medicine UK
This link will take you to a website which is not owned or controlled by Johnson & Johnson Innovative Medicine UK and where our privacy policy does not apply. Click below to continue.
We want to ensure people living with PAH in the UK are diagnosed early, supported holistically and able to access the care they need. Our work so far has brought unique perspectives, opportunities and capabilities that we hope will help us in creating new possibilities for the PAH community.”
Naomi Cragg
Business Unit Director, Johnson & Johnson Innovative Medicine UK
Our heritage in PAH
Our pioneering medicines and deep understanding of the complex pathways and molecular mechanisms associated with PAH have contributed to improving patient outcomes for PAH communities.
In June 2017, Actelion Pharmaceuticals Ltd became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Supported by Actelion’s 20-year heritage of pioneering innovation in PAH, we are working to reach more patients and aim to help tackle the diagnosis gap that can delay access to the care that patients need.
We bring to the field of PAH a remarkable track record in scientific discovery and a deep patient-centric focus.
In June 2017, Actelion Pharmaceuticals Ltd became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Supported by Actelion’s 20-year heritage of pioneering innovation in PAH, we are working to reach more patients and aim to help tackle the diagnosis gap that can delay access to the care that patients need.
We bring to the field of PAH a remarkable track record in scientific discovery and a deep patient-centric focus.
We are committed to partnering with those whose innovative thinking will bring new and creative solutions to the field of medicine
References
1: Humbert M et al, (2022), 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension; European Heart Journal; 00, 1–114. This link will take you to a website which is not owned or controlled by Johnson & Johnson Innovative Medicine UK and where our privacy policy does not apply. Click below to continue.
2: Office for National Statistics. UK population. Available at: https://www.ons.gov.uk/
. Last accessed November 2024.
You are now leaving Johnson & Johnson Innovative Medicine UK
3: Armstrong I, et al. The patient experience of pulmonary hypertension: a large cross sectional study of UK patients. BMC Pulm Med 2019; 19:67.
CP-486604 | November 2024